Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $5.02
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.50M
Market Cap
$283.92M
Enterprise Value$479.64M
Total Cash (Recent Filing)$69.80M
Total Debt (Recent Filing)$6.43M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 14, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding159,000,290
10 Day Avg. Volume1,619,038
30 Day Avg. Volume1,501,052
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)36.04
Price to Cash Flow (P/CF)-32.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.52
Forecast
1Y Price Target
$7.43Price Target Upside322.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Mereo Biopharma Group Plc News
PremiumCompany Announcements
Mereo BioPharma Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Mereo Biopharma Advances with Key Clinical Updates
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement commentary suggests a strong probability of success for the second interim analysis despite a high statistical threshold.
Financial PerformanceThe shares are trading at a market cap of less than 1.0x gross peak sales estimates for setrusumab in the EU, presenting a favorable valuation ahead of upcoming data.
Product DevelopmentMereo has been frequently communicating with the FDA and has not yet experienced any delays resulting from recent personnel changes at the agency.
Bears Say
CompetitionLow competition risk for setrusumab in osteogenesis imperfecta seems underappreciated.
Market ValuationRecent stock weakness could represent a buying opportunity ahead of topline results from the ongoing Phase 3 ORBIT in osteogenesis imperfecta.
Strategic PartnershipsMREO is in discussions with multiple potential partners for the development and commercialization of alvelestat.
---
Ownership Overview
1.34% Insiders
0.10% Mutual Funds
48.03% Other Institutional Investors
49.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $1.70 and its highest was $5.02 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $283.92M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is May 14, 2025 which is in 34 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Mar 26, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.003.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,000,290 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went up 0.851%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
---
Mereo Biopharma Group Plc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.43 (322.16% Upside)
$7.43 (322.16% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 844.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group Plc (MREO) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of rare and specialty diseases. The company's pipeline includes multiple clinical-stage programs across various therapeutic areas such as oncology, respiratory, and rare diseases. Mereo BioPharma aims to address unmet medical needs through its proprietary drug candidates, leveraging strategic partnerships and collaborations to advance its research and development efforts.
---
MREO Stock 12 Month Forecast
Average Price Target
$7.43
▲(322.16% Upside)
Technical Analysis
Best Analysts Covering MREO
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+70.09%
reiterated a buy rating 15 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +70.09% per trade.
---